These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 21762224)

  • 1. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.
    Barnes N; Pavord I; Chuchalin A; Bell J; Hunter M; Lewis T; Parker D; Payton M; Collins LP; Pettipher R; Steiner J; Perkins CM
    Clin Exp Allergy; 2012 Jan; 42(1):38-48. PubMed ID: 21762224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
    Pettipher R; Hunter MG; Perkins CM; Collins LP; Lewis T; Baillet M; Steiner J; Bell J; Payton MA
    Allergy; 2014 Sep; 69(9):1223-32. PubMed ID: 24866478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis.
    Straumann A; Hoesli S; Bussmann Ch; Stuck M; Perkins M; Collins LP; Payton M; Pettipher R; Hunter M; Steiner J; Simon HU
    Allergy; 2013 Mar; 68(3):375-85. PubMed ID: 23379537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459.
    Singh D; Cadden P; Hunter M; Pearce Collins L; Perkins M; Pettipher R; Townsend E; Vinall S; O'Connor B
    Eur Respir J; 2013 Jan; 41(1):46-52. PubMed ID: 22496329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial.
    Horak F; Zieglmayer P; Zieglmayer R; Lemell P; Collins LP; Hunter MG; Steiner J; Lewis T; Payton MA; Perkins CM; Pettipher R
    Allergy; 2012 Dec; 67(12):1572-9. PubMed ID: 23025511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial.
    Gonem S; Berair R; Singapuri A; Hartley R; Laurencin MFM; Bacher G; Holzhauer B; Bourne M; Mistry V; Pavord ID; Mansur AH; Wardlaw AJ; Siddiqui SH; Kay RA; Brightling CE
    Lancet Respir Med; 2016 Sep; 4(9):699-707. PubMed ID: 27503237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.
    Pettipher R; Vinall SL; Xue L; Speight G; Townsend ER; Gazi L; Whelan CJ; Armer RE; Payton MA; Hunter MG
    J Pharmacol Exp Ther; 2012 Feb; 340(2):473-82. PubMed ID: 22106101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
    Erpenbeck VJ; Popov TA; Miller D; Weinstein SF; Spector S; Magnusson B; Osuntokun W; Goldsmith P; Weiss M; Beier J
    Pulm Pharmacol Ther; 2016 Aug; 39():54-63. PubMed ID: 27354118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
    Busse WW; Wenzel SE; Meltzer EO; Kerwin EM; Liu MC; Zhang N; Chon Y; Budelsky AL; Lin J; Lin SL
    J Allergy Clin Immunol; 2013 Feb; 131(2):339-45. PubMed ID: 23174659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
    Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
    Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.
    Miller D; Wood C; Bateman E; LaForce C; Blatchford J; Hilbert J; Gupta A; Fowler A
    Allergy Asthma Proc; 2017 Mar; 38(2):157-164. PubMed ID: 28234053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment.
    Hall IP; Fowler AV; Gupta A; Tetzlaff K; Nivens MC; Sarno M; Finnigan HA; Bateman ED; Rand Sutherland E
    Pulm Pharmacol Ther; 2015 Jun; 32():37-44. PubMed ID: 25861737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
    Dahlén SE; Malmström K; Nizankowska E; Dahlén B; Kuna P; Kowalski M; Lumry WR; Picado C; Stevenson DD; Bousquet J; Pauwels R; Holgate ST; Shahane A; Zhang J; Reiss TF; Szczeklik A
    Am J Respir Crit Care Med; 2002 Jan; 165(1):9-14. PubMed ID: 11779723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PGD
    Kupczyk M; Kuna P
    Drugs; 2017 Aug; 77(12):1281-1294. PubMed ID: 28612233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma.
    Kuna P; Bjermer L; Tornling G
    Drug Des Devel Ther; 2016; 10():2759-70. PubMed ID: 27621597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial.
    Ramsay CF; Sullivan P; Gizycki M; Wang D; Swern AS; Barnes NC; Reiss TF; Jeffery PK
    Respir Med; 2009 Jul; 103(7):995-1003. PubMed ID: 19249198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.
    Philip G; van Adelsberg J; Loeys T; Liu N; Wong P; Lai E; Dass SB; Reiss TF
    J Allergy Clin Immunol; 2009 Nov; 124(5):942-8.e1-9. PubMed ID: 19748656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 2 study to evaluate the safety, efficacy and pharmacokinetics of DP2 antagonist GB001 and to explore biomarkers of airway inflammation in mild-to-moderate asthma.
    Ortega H; Fitzgerald M; Raghupathi K; Tompkins CA; Shen J; Dittrich K; Pattwell C; Singh D
    Clin Exp Allergy; 2020 Feb; 50(2):189-197. PubMed ID: 31659803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.